While there has been growing acknowledgement of the fact that our world is getting older, within the life sciences industry, geriatrics has often remained the
This article focuses on three critical considerations in the planning and development of drugs targeted at the geriatric population that present enormous opportunities for the forward thinking
This is the first in a series of posts which emphasizes how life science product manufacturers should be cognizant of the growing elderly population and
The crucial question when determining the fate of a mature product; where do we go from here? From the mid-point of the product lifecycle onward
In my last few posts I shared ideas on how to enhance product planning efforts to maximize the market potential for a product. This is
The life sciences industry is certainly experiencing stormy seas. However, today, the industry can celebrate a victory in the battle for innovation. Biogen’s approved label change for
The life science industry is facing tremendous challenges, and you don’t need to face them alone. There are numerous management consulting firms that will help
I’m a strong proponent of partnerships with life science companies and research institutions. I’m motivated by the inherent synergies of these partnerships, and the opportunities
In previous blog posts I made a strong point to look at research institutions as potential partners for product development and encouraged life science companies to “cast
Through clinical data gap analysis, a company can determine if it is truly necessary to follow the common paths being taken by the competition, jump
